Pembrolizumab-induced erythema multiforme requiring systemic immunosuppression

Intern Med J. 2021 Dec;51(12):2149-2150. doi: 10.1111/imj.15617.

Authors

Terri Shih¹, Shawn Shih², Mohammad Sharaf²

Affiliations

¹ David Geffen School of Medicine at University of California, Los Angeles, California, USA.
² Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts, USA.

PMID: 34939289
DOI: 10.1111/imj.15617

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Erythema Multiforme* / chemically induced
Erythema Multiforme* / diagnosis
Erythema Multiforme* / drug therapy
Humans
Immunosuppression Therapy
Immunotherapy

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab